Case series of chronic myeloid leukemia patients who maintained deep molecular response (DMR) with very low-dose ponatinib: experience in discontinuing low-dose ponatinib and treatment-free remission (TFR) outcomes

Jonathan Cohen, Alison Palumbo, Jason Wing, Michael C. Heinrich

Research output: Contribution to journalLetterpeer-review

1 Scopus citations
Original languageEnglish (US)
Pages (from-to)2511-2514
Number of pages4
JournalLeukemia and Lymphoma
Issue number10
StatePublished - Aug 23 2020

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this